pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
Summit Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
Summit Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Summit Therapeutics.
Summit Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AK112 Injection
Summit Therapeutics
Non-Squamous Non-small Cell Lung Cancer
1 trial -
Acupuncture
Summit Therapeutics
Fatigue
1 trial -
Drug: Ivonescimab Injection
Summit Therapeutics
Metastatic Colorectal Cancer (CRC)
1 trial -
Ivonescimab 10 mg/kg
Summit Therapeutics
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
1 trial -
Ivonescimab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
2 trials -
Ridinilazole
Summit Therapeutics
Clostridioides Difficile Infection
2 trials -
SMT112-3003
Summit Therapeutics
Metastatic Non-small Cell Lung Cancer
1 trial -
SMT112-3003
Summit Therapeutics
Metastatic Squamous Non-small Cell Lung Cancer
1 trial -
SMT112-3005
Summit Therapeutics
Metastatic colorectal cancer
1 trial
Frequently asked questions
How many clinical projects does Summit Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.